Stroke RSS

Filtered By:
Cancer: Lung Cancer
Therapy: Chemotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 15 results found since Jan 2013.

Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for non-small cell lung cancer: a case report.
We report about a 70-year-old male with metastatic non-small cell lung cancer who received vinorelbine as an outpatient. The patient presents with a cardiovascular risk profile. He was admitted to the hospital 3 days later with acute left-sided hemiplegia and hemianopia. Brain computed tomography (CT) demonstrated acute right hemispheric ischaemic stroke. Nine days after admission, the patient additionally suffered ST elevation myocardial infarction. A coronary angiogram demonstrated high grade stenosis of the right coronary artery treated with two bare-metal stents. Caution should be noted in patients who present with a c...
Source: Journal of Chemotherapy - November 18, 2015 Category: Cancer & Oncology Tags: J Chemother Source Type: research

P2-33-4 * lung cancer chemotherapy in patients undergoing daialysis
Conclusion: Chemotherapy for lung cancer patients undergoing dialysis were associated with severe hematological toxicity.It is urgent task to establish optimal cancer chemotherapy and management of adverse events.
Source: Annals of Oncology - October 19, 2014 Category: Cancer & Oncology Authors: Sato, K., Kuriyama, H., Sakamoto, H., Ebe, Y., Koike, T. Tags: Poster Session (Poster presentations categorized by each organ) Source Type: research

Clinical Reasoning: A 68-year-old man with a history of lung cancer presenting with right-sided weakness and aphasia
A 68-year-old man with paroxysmal atrial fibrillation on warfarin, left subclavian thrombosis treated with carotid-subclavian bypass, and lung adenocarcinoma treated with pneumonectomy, chemotherapy, and prophylactic cranial irradiation and in remission since 1987 was admitted to our neurocritical care unit with acute onset of right-sided weakness, expressive aphasia, and lethargy. On admission his temperature was 101.7°F, and initial blood pressure was 140/60 mm Hg. There was no nuchal rigidity. He was alert and mute with impaired comprehension. He had left gaze preference. Vision was impaired in the right field. Ther...
Source: Neurology - October 5, 2015 Category: Neurology Authors: Gupta, A., Etherton, M. R., McKee, K., Baker, J. M., Izzy, S., Feske, S. K. Tags: All Cerebrovascular disease/Stroke, Radiation therapy-tumor, All Epilepsy/Seizures RESIDENT AND FELLOW SECTION Source Type: research

Exercise 'most proven method' to prevent return of breast cancer
Conclusion This was a helpful summary of recent research into how lifestyle changes impact on the risk of breast cancer returning, but it does have some limitations. Researching lifestyle factors separately is always difficult as they tend to clump together, making it difficult to pick apart individual factors. For example, people who are more physically active tend to have a healthier diet and are less likely to drink excessive amounts of alcohol or smoke. While the researchers say many studies attempt to make adjustments for these confounding factors, it is difficult to know which studies did this and how successful they...
Source: NHS News Feed - February 22, 2017 Category: Consumer Health News Tags: Cancer QA articles Lifestyle/exercise Source Type: news

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
This report presents the case of a 60-year-old woman who was diagnosed with stage IV lung adenocarcinoma with asymptomatic brain metastases and commenced chemotherapy with cisplatin/pemetrexed (CDDP/Pem). She experienced tonic-clonic convulsions on day 9 of the first cycle, which were accompanied by increased blood pressure (173/69 mm Hg) and headache. Therefore, brain MRI was performed to check for stroke or progression of brain metastatic foci. T2-weighted, FLAIR, and ADC map images showed high-intensity areas in the subcortical region of the bilateral parieto-occipital lobes, leading to a diagnosis of posterior reversib...
Source: Case Reports in Oncology - March 9, 2017 Category: Cancer & Oncology Source Type: research

Nivolumab-induced posterior reversible encephalopathy syndrome
A 47-year-old woman with metastatic, poorly differentiated lung cancer with neuroendocrine features was brought to the hospital after 4 days of nausea, vomiting, disorientation, and 1 generalized tonic clonic seizure. On examination, her blood pressure was 148/95 mm Hg, heart rate 95 bpm, and temperature 36.4°C. She was encephalopathic and had cortical blindness. She had no history of seizures or visual impairment. MRI brain without contrast showed changes consistent with posterior reversible encephalopathy syndrome (PRES; figure, A). She had been on nivolumab, of which she had received 2 doses; the last dose was 24 da...
Source: Neurology Clinical Practice - October 16, 2017 Category: Neurology Authors: Hussein, H. M., Dornfeld, B., Schneider, D. J. Tags: MRI, Other cerebrovascular disease/ Stroke, All Clinical Neurology, Chemotherapy-tumor Case Source Type: research

Black pleural effusion as the presenting feature of lung cancer.
Conclusion: In the present case, the black stain most likely results from intrapleural haemolysis following haemorrhage. Pleural fluid bilirubin may be useful in evaluating pleural effusion, especially if black.
Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Fernandes, V., Alfaro, T. M., Cruz, C., Cordeiro, C. R. Tags: Clinical Problems Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Informing Radiotherapy Decisions in Stage I/IIa Hodgkin Lymphoma: Modelling Life Expectancy Using Radiation Dosimetry
Blood Adv. 2021 Dec 6:bloodadvances.2021006254. doi: 10.1182/bloodadvances.2021006254. Online ahead of print.ABSTRACTIn recent randomized trials, omitting consolidative radiotherapy in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial follow-up is therefore necessary to inform current treatment decisions. To this end, we developed a microsimulation model to estimate lifetime quality-adjusted life years (QALYs) after combined modality treatment (CMT) or ...
Source: Cancer Control - December 6, 2021 Category: Cancer & Oncology Authors: David Andrew Jones Paolo Candio Rebecca Shakir Georgios Ntentas Johanna Ramroth Alastair M Gray David John Cutter Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - December 31, 2022 Category: Cancer & Oncology Source Type: research